glp 1/gip agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight Triple GLP-1 / GIP /

Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis

This work was supported by the Lundbeck Foundation (fellowship R238-2016-2859), the BioInnovation Institute (grant number NNF20OC0063538) and the Novo Nordisk Foundation (grant numbers NNF17OC0026114 and NNF22OC0073778)

semaglutide was approved for marketing in the United States in September 2017 66

Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group